Anti-MG7 chimeric antigen receptor T cell therapy - Shanghai Genechem

Drug Profile

Anti-MG7 chimeric antigen receptor T cell therapy - Shanghai Genechem

Alternative Names: Anti-MG7 CAR-T cells - Shanghai Genechem; Ultrasound-guided Intra-tumor Infusion of MG7-CART cells

Latest Information Update: 26 Aug 2016

Price : $50

At a glance

  • Originator Shanghai Genechem
  • Developer Shanghai Genechem; Xijing Hospital
  • Class Cancer vaccines; CAR-T cell therapies
  • Mechanism of Action Cytotoxic T lymphocyte stimulants; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Liver metastases

Most Recent Events

  • 01 Jun 2016 Phase-I/II clinical trials in Liver metastases (In adults) in China (Intratumoural) (NCT02862704)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top